Mycobacterial Metabolic Pathways as Drug Targets: A Review by Jemal Adem, Ebsa Bushra
Advances in Life Science and Technology                                                                                                 www.iiste.org 




Mycobacterial Metabolic Pathways as Drug Targets: A Review 
 
Ebsa Bushra and Jemal Adem 




Mycobacterium is acid fast genus of bacteria that include many pathogenic and non pathogenic species. 
Treatment is made quite difficult by the presence of metabolically silent, persistent or dormant bacteria within 
host lesions, which are not susceptible to the anti-mycobacteria drugs that usually kill growing bacteria but not 
persistent mycobacteria. The emergence of antibiotic resistance strains has raised the need towards the 
development of new antibiotics or drug molecules which can kill or suppress the growth of pathogenic 
Mycobacterium species. Novel efforts in developing drugs that target the intracellular metabolism of M. 
tuberculosis often focus on metabolic pathways that are specific to mycobacterium. Potential drug targets were 
also identified from pathways related to lipid metabolism, carbohydrate metabolism, amino acid metabolism, 
energy metabolism, vitamin and cofactor biosynthetic pathways and nucleotide metabolism. The objective this 
paper was to review those mycobacterium metabolic pathways as drug target and the problems of current TB 
drugs. The crucial problems of current TB therapy are development of multi-drug resistance and inefficiency of 
current TB drug to kill or inhibit non growing mycobacterium. The identification of drug target from that unique 
metabolism of mycobacterium is crucial to develop new drug for persistent and latent infection of tuberculosis. 
Despite an urgent need for new therapies targeting persistent bacteria, our knowledge of bacterial metabolism 
throughout the course of infection remains rudimentary. Therefore, better understanding on the physiology of 
mycobacterium during the latent period will help in the identification of new drug targets that can act on the 
persistent mycobacterium. Identification of these targets will to produce new drugs against tuberculosis that will 
overcome the limitations of existing drugs such as, prolonged chemotherapy, failure against persistent infection 
and multidrug resistance. 
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INTRODUCTION 
The genus Mycobacterium comprises non pathogenic and pathogenic species that infect both humans and 
animals. The genus Mycobacterium encompasses 71 validly named species and 32 species are known to be 
pathogenic to humans or animals [1]. Tuberculosis is a mycobacterium infection that affects a wide range of 
mammals including humans. Mycobacterium tuberculosis is a tenacious and remarkably successful pathogen that 
has latently infected one third of the world population. Each year there are eight million of new tuberculosis (TB) 
cases and two million deaths [2].  
M. bovis is the causative agent of bovine tuberculosis, a chronic and occasionally fatal infectious 
disease primarily infecting cattle and other livestock; but is capable of infecting a wide range of mammals and 
other vertebrates, including humans [3]. M. bovis is very closely related to M. tuberculosis, a virulent tubercle 
bacillus estimated to infect a third of the world’s population and cause the deaths of 1.4 million people each year. 
In an attempt to prevent tuberculosis infections more than 3 billion individuals have been immunized with M. 
bovis BCG, a live attenuated derivative of M. bovis [4]. 
The increasing emergencies of drug resistance tuberculosis and immune compromising disease and 
allows latent infection to reactivate or render individual more susceptible to TB pose further challenges for 
effective control of the disease in human [5].  Ethiopia is one of the 27 high MDR-TB countries; it is ranked 15th 
with more than 5000 estimated MDR-TB patients each year. According to the WHO report, the prevalence of 
MDR-TB has been 2.8% in newly diagnosed patients; it is reportedly even higher in patients who have 
previously received anti-TB treatment 21% [6]. Published studies on MDR-TB are increasingly available 
worldwide, but accurate data on drug-resistant TB in Ethiopia is limited [7]. Some recent study shows that a 
quarter of TB patients were having persistent TB clinical signs after receiving there commended drugs and 
duration of therapy. Most of the respondents were living in the rural community and they might not report early 
to health institutes in Ethiopia [8] 
Currently, TB chemotherapy is made up of a cocktail of first-line drugs; isoniazid (INH), rifampin 
(RIF), pyrazinamide (PZA) and ethambutol (EMB), given for six months [9, 10]. If the treatment fails as a result 
of bacterial drug resistance, or intolerance to one or more drugs, second-line drugs are used, such as para-
aminosalicylate (PAS), kanamycin (KAN), fluoroquinolones (FQ), capreomycin (CAP), ethionamide (ETA) and 
cycloserine (CYS), that are generally either less effective or more toxic with serious side effects [9].  
Agents with unclear roles in drug-resistant TB treatment are called third-line anti-TB drugs such as 
clofazimine, linezolid, amoxicillin/clavulanate, thioacetazone, and imipenem/cilastatin and high-dose isoniazid. 
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Treatment is made quite difficult by the presence of metabolically silent, persistent or dormant bacteria within 
host lesions, which are not susceptible to the anti-mycobacterial drugs that usually kill growing bacteria but not 
persistent bacteria [11] 
Using metabolic pathway information as the starting point for the identification of potential targets has 
its advantages as each step in the pathway is validated as essential function for the survival of the bacterium [12]. 
It is widely accepted that TB is a dynamic disease that results from combination of phenotypically diverse 
population of bacilli in continually changing host environment. The release of complete genome sequence of 
Mycobacterium has facilitated the development of more rational and specific methods to search for new drug 
targets and vaccine candidates [13]. 
The recent rise in TB cases and especially the increase of drug resistant mycobacterium indicate an 
urgent need to develop new anti-TB drugs. The long duration of TB therapy is a consequence of persistent M. 
tuberculosis, not effectively killed by current anti-TB agents. Recent advances in the knowledge of the biology 
of the organism and the availability of the genome sequence give an opportunity to explore a wide range of novel 
targets for drug design. Metabolic studies on mycobacterium have been important areas of the investigation to 
identify that metabolic pathway as drug target to design more effective [14]. The objective of this paper was to 
review on mycobacterium metabolic pathways as drug targets and problems of current TB drug. 
 
METABOLIC PATHWAYS USED AS DRUG TARGETS 
Mycobacterium metabolic pathways which do not appear in the host but present in the pathogen are identified as 
pathways unique to mycobacterium as compared to the host. Enzymes in these unique pathways as well as 
enzymes involved in other metabolic pathways under carbohydrate metabolism, amino acid metabolism, lipid 
metabolism, energy metabolism, vitamin and cofactor biosynthesis and nucleotide metabolism are important to 
identify novel drug targets [15]. An important question to be addressed while choosing potential drug targets is 
whether the biochemical pathway to be targeted is unique to bacteria. These biochemical pathways which are; 
Peptidoglycan biosynthesis, Mycobactin biosynthesis, d-alanine metabolism, thiamine metabolism and 
polyketide sugar unit biosynthesis, all absent in the host and therefore unique to the pathogen [16]. Design and 
targeting inhibitors against these nonhomologous sequences could be the better approach for generation of new 
drugs. Thus total five unique metabolic pathways have been taken in M. tuberculosis [17].  
 
Mycobactin biosynthesis: 
One of the key host defense mechanism is the production of siderocalins that sequester iron-laden siderophore 
and Mycobacterium replicates poorly in the absence of these siderophores [18].To overcome iron deficiency 
imposed by the host defensive system, bacteria have evolved iron acquisition systems where small molecules 
called siderophores, which bind extracellular iron, are secreted. These get reabsorbed along with the bound iron 
through specific cell surface receptors. The Mtb siderophore pathway is well studied and consists of secreted 
siderophore termed Mycobactin [19].The importance of Mtb iron uptake was highlighted by evidence that the 
mode of action of one of the earliest anti-TB drugs, p-amino salicylic acid, was inhibition of siderophores 
biosynthesis [20]. 
Pathogenic Mycobacterium species produces the mycobactin class of siderophore, which contains a 
salicylic acid derived moiety. Therefore, these siderophores used for mycobactin biosynthesis, d-alanine 
metabolism and Peptidoglycan biosynthetic pathways [18].  Mycobactin G (Mycobactin lysine-N6-hydroxylase), 
which catalyzes the hydroxylation of lysine moiety in mycobactin synthesis, is the potential target in this 
pathway. It has been shown that there is no possibility of bacterial survival on more than a few generations if it is 
deprived of iron. So to acquire iron from host, it relies on a siderophores mediated pathway [21].  
Disruption of mycobactin biosynthetic pathway may affect the survival of the bacterium under these 
conditions of iron limitation. It has been shown that siderophore production is also important for the virulence of 
M. tuberculosis. But some very recent research showed that even though siderophore are unique they are not the 
only machinery employed by the mycobacterium to acquire iron from vicinity. Besides non-heme iron uptake, 
mycobacteria also have a heme iron uptake pathway. Initial evidence for this pathway was based on the 
observation that a recombinant bacillus calmette-guerin harboring a defective siderophore biosynthetic pathway, 
replicated slowly in mice, suggesting it acquires heme iron [22]. The mycobacterium can utilize heme as an Iron 
source [23].  
An Mycobacterium tuberculosis heme-uptake system has been defined that consists of the secreted 
protein known as hypothetical protein (Rv0203)  and the trans membrane proteins called possible membrane 
transport protein (MmpL3 and MmpL11) [24]. Some recent experiments showed that hypothetical protein 
transfers heme to both MmpL3 and MmpL11 during Mycobacterium tuberculosis heme uptake making these 
proteins potential targets for TB drugs [25]. 
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The cell envelope of mycobacterium is made up of three major components: plasma membrane, cell wall (MAPc) 
and polysaccharide rich capsule like materials. The cell wall of mycobacterium is made up of cross-linked 
peptidoglycan which is covalently linked to Arabinogalactan chain via polyketide linkage unit. Arabinogalactan 
in turn is esterified to variety of alpha-alkyl, beta-hydroxyl mycolic acid. The unique nature of the MAPc leads 
to the conclusion that enzyme that synthesizes these structures yield many number potential new drug targets [26]   
Mycobacterium is surrounded by a lipid-rich outer capsule that protects it from the toxic radicals and hydrolytic 
enzymes produced as defense by macrophages [22]. The peptidoglycan layer of the cell wall serves as a base for 
the lipid-rich capsule. Peptidoglycan is the polymeric mesh of the bacterial cell wall, which plays a critical role 
in protecting the bacteria against osmotic lysis. The currently used anti-mycobacterial drugs are isoniazid (INH) 
and ethambutol (EMB) were target cell wall biosynthesis. Isoniazid is known to inhibit mycolic acid synthesis 
[26], where as ethambutol inhibits the polymerization step of arabinan biosynthesis of Arabinogalactan. 
Arabinosyl transferase, encoded by embB, an enzyme involved in synthesis of Arabinogalactan, has been 
proposed as the target of ethambutol [27] 
The primary target of inhibition is the cell wall mycolic acid synthesis pathway, where enoyl ACP (acyl 
carrier protein) reductase (InhA) was identified as the target of INH inhibition. The active species for InhA 
inhibition has been found to be isonicotinic acyl radical, which reacts with NAD to form INH-NAD adduct and 
then inhibits the InhA enzyme. The reactive species produced during INH activation could also cause damage to 
DNA, carbohydrates, and lipids and inhibit NAD metabolism. INH is a prodrug that requires activation by M. 
tuberculosis catalase-peroxidase (KatG) to generate a range of reactive oxygen species and reactive organic 
radicals, which then attack multiple targets in the tubercle bacillus. Mutations in KatG involved in INH 
activation in the INH target InhA and Ndh II (NADH dehydrogenase II) could all cause INH resistance. KatG 
mutation is the major mechanism of INH resistance [26].   
 
D-Alanine metabolism: 
D-alanine is a necessary precursor in the bacterial peptidoglycan biosynthetic pathway. The naturally occurring 
L-isomer is racemized to its D-form through the action of a class of enzymes called alanine racemases. These 
enzymes are ubiquitous among prokaryotes and are absent in eukaryotes which makes them a logical target for 
the development of antibiotics. The d-alanine–d-alanine ligase (ddlA) and alanine racemase (alr) from this 
pathway have no similarity to any of the host proteins.  Alanine racemase has been identified as a target as all the 
bacteria investigated contained either one or two alanine racemase genes [28].  
However, in mycobacterium, there is a single alanine racemase gene. These two enzymes catalyze the 
first and second committed steps in bacterial peptidoglycan biosynthesis. Alanine racemase is a pyridoxal 50-
phosphate-containing enzyme that catalyzes the racemization of L-alanine into D-alanine, a major component in 
the biosynthesis of Peptidoglycan [29]. One alanine racemase inhibitor, the structural d-alanine analogue d-
cycloserine has been marketed clinically. Both alanine racemase and D-Ala-D-Ala ligase are targets of D-
cycloserine, a second-line anti -TB drug. Although, this is supposed to be an excellent inhibitor of 
mycobacterium and other pathogenic species bacteria, serious side effects especially CNS toxicity has limited its 
use [30]. 
 
Polyketide sugar unit biosynthesis: 
AG and PG chains are tethered via a linker region known as Phosphoryl-N-acetyl-glucosaminosyl-rhamnosyl 
[31]. Arabinogalactan a heteropolysacharide is connected via a linker disaccharide called polyketide (a-L-Rha--
a-D-Glc-NAc-1 -phosphate) to the sixth position of a muramic acid residue in the peptidoglycan. The reaction is 
catalyzed: by the enzyme rhamnosyl transferase [32].  Rhamnose residue and large portion of arabinogalactan 
polysaccharide are synthesized on GIcNAc-P-P-decaprenyl carrier lipid [27]. 
The eventual transfer of the arabinogalactan-Rha-GlcNac-phosphate unit to the O-sixth of a muramic 
acid places the polysaccharide in mass on to the peptidoglycan. The biosynthesis of arabinogalactan in M. 
tuberculosis begins with the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetyl glucosamine to 
prenylphosphate followed by an addition of rhamnose (Rha) from dTDP-Rha, forming a linker region of the 
arabinogalactan [33]. L-rhamnose transferase (WbbL) is an enzyme that utilizes dTDP-Rha as a substrate for the 
formation of final product L-rhamnose which plays a crucial role in the linkage of cell wall. The biosynthesis of 
dTDP-rhamnose is catalysed by four enzymes coded by the genes; RmlA (Rv0334), RmlB (Rv03464), RmlC 
(Rv3465) and RmlD (Rv3266) and ultimately synthesizes dTDP rhamnose from glucose-1-phosphate. Among 
these genes RmlC has no human homologue. RmlC codes for dTDPd-glucose-3, 5-epimerase which is involved 
in the arabinogalactan biosynthesis [32].  
 
Targets from other pathways: 
Even amongst the pathways shared by the host and the pathogen, there are several proteins from pathways 
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involved in lipid metabolism, carbohydrate metabolism, amino acid metabolism, energy metabolism, vitamin 
and cofactor biosynthetic pathways and nucleotide metabolism which do not bear similarity to host proteins. 
While some of them are known to be associated with virulence or important for persistence or vital for 
mycobacterial metabolism, others should further be investigated for their potential to be drug targets [34] 
There are many enzymes from the glyoxylate by pass, which is important for mycobacterial persistence. 
Among these enzymes the most important are Isocitrate Lyase and Malate Dehydrogenase.  It has been proposed 
by Waynes and Lin [35] that the enzymes of the glyoxylate cycle are activated during adaptation to the low 
oxygen environment of the granuloma. The glyoxylate by pass allows the bacterium to synthesize carbohydrates 
from fatty acids. Succinate and glyoxylate produced by this cycle are supplied to the TCA cycle and 
gluconeogenesis. Disrupting this pathway by targeting these enzymes has a potential in the treatment of latent 
tuberculosis infections. 
Strikingly, a functional glyoxylate cycle appears to be required for the intracellular survival (persistence) 
of Mycobacterium tuberculosis. Despite past claims for enzymatic activity in vertebrates and the human genome 
have no apparent genes for key glyoxylate cycle enzymes. The absence of these enzymes provides potential 
targets for drugs directed against bacterial and fungal pathogens or parasites [36]. 
 
Identification of unique pathways and potential drug Target: 
So far, more than 100 bacterial genomes have been sequenced. As bacterial genome sequences become available, 
there is increasing interest in developing new antibacterial agents using genomics-based approaches [14]. No 
new anti-tuberculosis drugs have been developed for well over 20 years. In view of the increasing development 
of resistance to the current leading anti-tuberculosis drugs, novel strategies are desperately needed to avert the 
“global catastrophe” forecast by the WHO. The first bacterial genome was sequenced by Fleischmann and 
colleagues at the Institute for Genomic Research (IGR) in 1995 [37].  
The recent developments in microarray technology, signature tag mutagenesis, mycobacterial 
transposon mutagenesis and gene knock-out technology provide important tools to identify new drug targets. 
Microarray has been used to identify M. tuberculosis genes that are induced by INH and ETH and by INH [39]. 
Microarray was also used to identify genes that are switched on in the Wayne “dormancy” model under hypoxic 
and nitric oxide stress conditions a discovery that led to the identification of a 48-gene “dormancy regulon” 
controlled by DosR [40]. 
 
Identification of essential genes: 
Essential genes are those indispensable for the survival of an organism, and their functions are considered as 
foundation of life. Total 55 enzymes out of all were found to be essential for M. tuberculosis life cycle. These 
targets were found to be potential targets and could be considered for rational drug design. Using metabolic 
pathway information as the starting point for the identification of potential targets has its advantages as each step 
in the pathway is validated as the essential function for the survival of the bacterium [41]. 
 
Identification of drug target’s functions using UniProt (Universal Protein Resource): 
The sub cellular localization analysis of all supposed essential and unique enzymes of M. tuberculosis were 
evaluated by UniProt server. As it was suggested that, membrane associated protein could be the better target for 
developing vaccines. After functional analysis unique enzymes involved in cellular components like cell wall, 
cytoplasm, extra cellular region, plasma membrane, and so forth, their biological processes and their functions 
have been retrieved. Further, the functional analysis using Uniprot showed involvement of all the unique 
enzymes in the different cellular components [17]. 
The complete genome sequence of M. tuberculosis provides an opportunity for a more focused and 
planned approach towards the identification of new drug targets [13].The availability of the M. tuberculosis 
genome sequence opens up a new opportunity to understand the biology of the organism and provides a range of 
potential drug targets [12]. 
 
POSSIBLE DRUG TARGETS 
Desirable targets should be involved in vital aspects of bacterial growth, metabolism and viability, whose 
inactivation will lead to bacterial death or inability to persist [42]. In recent years, a number of new genes and 
their products in M. tuberculosis have been identified, which can be possible drug targets for mycobacterium. 
The gene products that control vital aspects of mycobacterial physiology like, metabolism, persistence, virulence, 
two component system and cell wall synthesis would be attractive targets for new drugs. A large number of 
genes are being studied in the search for new drug targets using various approaches [13]. 
Recent developments in mycobacterial molecular genetics tools such as transposon mutagenesis, 
signature-tagged mutagenesis, gene knockout, and gene transfer will facilitate the identification and validation of 
new drug targets essential for the survival and persistence of tubercle bacilli not only in vitro but also in vivo. 
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Below is a list of potential targets where by new drugs may be developed for improved treatment of TB [14]. 
Because of the drug-resistant TB problem, it is important to develop new drugs that inhibit novel targets that are 
different from those of currently used drugs. To avoid significant toxicity, the targets of inhibition should be 
present in bacteria but not in the human host. Although modification of existing drugs for improved half-life, 
bioavailability, or drug delivery may be of some use, agents obtained by this approach may have a cross-
resistance problem. Similarly, targeting existing TB drug targets for drug development may be limited value 
because of potential cross-resistance [13]  
 
Targeting Mycobacterial persistence: 
Mycobacterial persistence refers to the ability of tubercle bacillus to survive in the face of chemotherapy and/or 
immunity [43]. The nature of the persistent bacteria is unclear but might consist of stationary phase bacteria, 
post-chemotherapy residual survivors or dormant bacteria that do not form colonies upon plating [11]. The 
presence of such persistent bacteria is considered to be the major reason for lengthy therapy. A lot of research 
activity is currently aimed at understanding the biology of persistence of the tubercle bacillus and developing 
new drugs that target the persistent bacteria [44]. 
The glyoxylate cycle was described by Kornberg and Madsen as a “modified tricarboxylic acid (TCA) 
cycle”, with which it shares malate dehydrogenase, citrate synthase, and aconitase activities. However, instead of 
the two decarboxylation steps of the TCA cycle the key enzymes of the glyoxylate cycle, namely isocitrate lyase 
and malate synthase, convert isocitrate and acetyl-CoA into succinate and malate. Isocitrate lyase splits the C6-
unit into succinate and glyoxylate, which in turn is condensed by malate synthase with acetyl-CoA generating 
free CoA-SH and malate. The latter is used by malate dehydrogenase to continue the cycle and succinate is 
released as net product. The intermediate glyoxylate provides the name for this metabolic pathway, which allows 
cells to convert two acetyl-CoA units generated by various catabolic processes into C4-units (succinate) which 
can be used to replenish the TCA cycle or to function as precursors for amino acid biosynthesis carbohydrate 
biosynthesis. Thus, the glyoxylate cycle serves as a link between catabolic activities and biosynthetic capacities 
and enables cells to utilize fatty acids or C2-units such as ethanol or acetate as sole carbon source [36]. ICL 
catalyzes the conversion of isocitrate to glyoxylate and succinate and is an essential enzyme for fatty acid 
metabolism in the glyoxylate shunt pathway [45]. Survival of M. tuberculosis in the adverse in vivo environment 
requires utilization of C2 substrates generated by β-oxidation of fatty acids as the carbon source [46].  ICL was 
induced in the Wayne “dormancy” model, inside macrophages and in the lesions of the human lung. ICL is not 
essential for the viability of tubercle bacilli in normal culture or in hypoxic conditions, but it is needed for long-
term persistence in mice. The phenotype of the isocitrate lyase mutant a pronounced defect in long-term 
persistence, suggests that a drug targeting the enzymes of the glyoxylate cycle might be useful in treating the 
latent infection that affecting perhaps one-third of the planet as well [47]. 
Using a transposon mutagenesis approach based on changes in colony morphology, a gene called pcaA 
encoding a novel methyl transferase involved in the modification of mycolic acids in mycobacterial cell wall was 
identified [14]. Although the PcaA knockout mutant grew normally in vitro and replicated in mice initially like 
the parent strain, the mutant was defective in persisting in mice and could be a target for drug design against 
persistent bacilli [48]. 
PcaA is required for cording and mycolic acid cyclopropane ring synthesis in the cell wall of both BCG 
and MTB. The site-specific cyclopropane modification of mycolic acids could be an important determinant of 
the interaction between M. tuberculosis and the host. Since this modification of mycolic acids is absent in non-
pathogenic mycobacteria, the phenotypes of the ∆pcaA strain suggest that the cyclopropyl modification system 
evolved to mediate principal virulence functions such as interaction with host innate immune receptors 
recognition [49] also have a profound effect on the function of these lipids as important virulence factors of the 
bacteria.   
RelA (ppGpp synthase) is critical for the successful establishment of persistent infection in mice by 
altering the expression of antigenic and enzymatic factors that may contribute to successful latent infection. A 
recent microarray study has found that DosR controls the expression of a 48-gene “dormancy regulon,” which is 
induced under hypoxic conditions and by nitric oxide [50]. DosR is a transcription factor of the two component 
response regulator class and the primary mediator of a hypoxic signal within MTB, used to control a 48-gene 
regulon involved in MTB survival under hypoxic conditions have been identified and could be good  targets for 
development of drugs that target persistent bacilli [51]. 
Rv2421c transfers phosphorous groups in nicotinate/nicotinamide salvage and de novo synthesis to 
convert necotinamide to nicotinic acid. Rv2043c of this pathway is the target of the highly effective drug PZA 
that kills persistent bacilli in the initial phase of TB therapy. Mutations in the encoding gene pncA confer 
resistance to PZA. Successful inhibition of Rv2421c could thus help to eradicate slowly growing persistent 
bacilli in TB infection [52]. 
Genes encoding, NadD and NadE enzymes, conserved among bacterial species and proven to be 
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essential in M. Tuberculosis are attractive and actively pursued drug targets [53]. The  disruption of NAD 
production in the cell via genetic suppression of the essential enzymes (NadD and NadE) involved in the last two 
steps of NAD biogenesis would lead to cell death, even under dormancy conditions results suggest that targeting 
NAD biosynthesis could lead to production of highly effective bactericidal antituberculosis compounds [54]. 
 
Targeting essential Genes: 
Essential genes are genes whose inactivation leads to non-viability or death of the bacteria. Transposon 
mutagenesis and signature-tagged mutagenesis have been used to identify genes essential for M. tuberculosis 
growth in vitro and survival in vivo [41]. Transposon mutagenesis is a biological process that allows genes to be 
transferred to a host organism's chromosome, interrupting or modifying the function of an extant gene on the 
chromosome and causing mutation. Signature tagged mutagenesis is a genetic approach that was developed to 
identify novel bacterial virulence factors. In a recent study, 614 genes, about one-sixth of the total number of 
genes in M. tuberculosis, were found to be essential for in vitro growth, whereas 194 genes were demonstrated to 
be essential for in vivo survival in mice [55]. 
The genes that are essential for survival in vitro and in vivo are grouped into the following categories: 
lipid metabolism; carbohydrate and amino acid transport and metabolism; inorganic ion transport and 
metabolism; nucleotide transport and metabolism; energy production and conversion; secretion; cell envelope 
biogenesis; cell division; DNA replication; recombination and repair; transcription and translation; post-
translational modification; chaperones; coenzyme metabolism; and signal transduction [41]. 
However, the function of a significant number of essential genes is unknown. Targeted knockout of 
specific genes is also a valuable approach to identifying essential genes, in other words, those whose disruption 
leads to non-viability of the bacilli. These essential mycobacterial genes should be good targets for TB drug 
development [56]. 
 
Targeting energy production pathway: 
All bacteria require energy to remain viable. Although the energy production pathways in M. tuberculosis are not 
well characterized, their importance as drug targets is demonstrated by the recent finding that PZA acts by 
disrupting membrane potential and depleting energy in M. tuberculosis. PZA is a frontline TB drug that is more 
active against non-growing persistent bacilli than growing bacilli and shortens TB therapy. That energy 
production or maintenance is important for the viability of persistent non-growing tubercle bacilli in vivo [51]. 
The recent discovery of the highly effective TB drug diarylquinoline also highlights the importance of 
energy production pathways for mycobacteria. The target for diarylquinoline was proposed to be the 
mycobacterial F1F0 proton ATP synthase, which is a new drug target in mycobacteria. It is likely that energy 
production pathways, such as the electron transport chain, glycolytic pathways and fermentation pathways, could 
be good targets for TB drug development [56]. 
Isocitrate lyase and malate dehydrogenase are an important enzyme in this category and also an 
important drug target. ICL is involved in energy production via the metabolism of acetyl-CoA and propionial 
CoA of the glyoxilate pathway. Inactivation of the icl gene leads to attenuation of both persistent and virulent 
strains of M. tuberculosis [45]. 
Five candidates, Rv2984, Rv2194, Rv1311, Rv1305 and Rv2195, map to the oxidative phosphorylation 
pathway. The target Rv1854c (gene ndh) in this pathway is the target for INH and several mutations in this gene 
account for INH resistant cases. Inhibiting any of the five proposed targets could disrupt the pathway and 
eliminate M. tuberculosis by reducing its limited ATP availability during dormancy [52] 
 
Targeting virulence factors: 
Despite intensive research efforts, there is little information about the molecular basis of mycobacterial virulence. 
Undoubtedly, one requisite to classify a gene as a virulence factor is that its absence attenuates the virulence of 
the microorganism in an in vivo model [48]. A number of genes have been identified, using different techniques 
like allelic exchange, signature tagged mutagenesis, and anti-sense RNA, that show a role in the virulence of M. 
Tuberculosis. Some of these genes include Cell Envelope Protein erp (Rv3810) .Exported repetitive protein (erp) 
which has been shown to be essential for the multiplication of mycobacteria during the acute phase of infection 
in the mouse model [49]. 
Recently, two gene clusters were identified and shown to be important for the growth of mycobacteria 
in the lungs during the early phase of infection. This gene cluster is involved in the synthesis (fadD28) and 
export (mmpL7) of a complex cell wall associated lipid, phthiocerol dimycocerosate [57]. Among the secreted 
proteins of M. tuberculosis which could act as virulence factors are a series of phospholipases C, lipases and 
esterase which might attack cellular or vacuolar membranes as well as several proteases [35].. Notable amongst 
these are phospholipases plcA, plcB, plcC and serine esterase [33] 
But, inhibition of virulence factors may not be lethal because they may not essential to the pathogen. 
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The other very important hurdle in this approach is that drugs that target virulence factors may be of very little 
use if the disease has already been established. However, inhibitors of these virulence gene products may be used 
in combination with existing drugs to improve the regime of chemotherapy [58]. 
 
Targeting two-component systems: 
Mycobacterial disease is characterized by the lack of involvement of classical virulence factors; rather a dynamic 
balance between host and pathogen defines the outcome of an infection. Therefore those mycobacterial genes 
that confer an advantage to the organism in this ongoing battle would qualify as virulence factors. Infection of 
macrophages constitutes an early stage in the host pathogen encounter. Obvious candidates among 
mycobacterium genes that can mastermind the intracellular survival and multiplication within macrophages as 
also the shutdowns of mycobacterium during persistence are signal transduction systems, in particular TCS. 
Therefore in vitro infection models have been used extensively to delineate the role of TCS during the stage of 
pathogen macrophage interaction. Animal models have also been used to study the effect of defined mutations in 
TCS on growth and virulence of the mycobacterial strains [1]. 
Two-component systems (TCS) are vital components of signal transduction systems in a number of 
organisms. It consists of a sensor kinase that senses external signals and transmits the signals to the response 
regulator. The response regulator interacts with transcription factors which in turn will switch on/off a number of 
genes [59]. The mycobacterial genome encodes several two-component systems, which consist of histidine 
kinases and their associated response regulators. These control the expression of target genes in response to 
stimuli that are involved in chemotaxis, phototaxis, osmosis, nitrogen fixation and intracellular survival [60]. 
The magnesium transporter (MtrA) and histidine kinases (SenX3) that are essential for mycobacterial virulence 
and persistence in mice, could also be good targets for the development of new drugs for persistent TB bacteria 
[61]. 
It has been shown that the inactivation of mtrA component of mtrA-mtrB complex of M. tuberculosis 
H37Rv was possible only in the presence of a functional copy of mtrA, suggesting that this response regulator is 
essential for the viability of M. tuberculosis [62]. 
Interestingly, another two-component system, devR-devS, was found to be over expressed in a virulent 
strain, H37Rv [63]. Disruption of the phoP component of the PhoP/PhoR in M. tuberculosis resulted in a mutant 
strain with impaired multiplication in the host.  This mutant was also found to be attenuated in vivo in a mouse 
model, suggesting that PhoP is required for intracellular growth of M. tuberculosis. These observations 
collectively suggest that TCS in M. tuberculosis could be important drug targets [64]. 
 
Targeting cell wall synthesis:  
The mycobacteria cell wall is a complex structure that is required for cell growth, resistance to antibiotics and 
virulence [65]. The cell wall acts as an exceptional permeable barrier and it requires robust biosynthetic 
machinery for its formation. Targeting the enzymes of cell wall biosynthetic pathway is a very reasonable 
strategy because the homologs of these enzymes are absent in mammalian system [66].  
It is composed of three distinct macromolecules; peptidoglycan, arabinogalactan and mycolic acids 
which are surrounded by a non-covalently linked outer capsule of proteins and polysaccharides [67]. The 
outermost, the mycolic acids are thought to be significant determinant of virulence in Mtb because they prevent 
attack of mycobacteria by cationic proteins, lysozyme and oxygen radicals in the phagocytic granule [27]. The 
mycolic acids are esterified to the middle component, arabinogalactan, a polymer composed primarily of D -
galactofuranosyl and D-arabinofuranosyl residues. AG is connected via a linker disaccharide, a-L-rhamnosyl-a-
D-acetyl-glucosaminosyl-1 -phosphate, to the sixth position of a muramic acid residue of peptidoglycan [32], 
which is the innermost of the three cell wall core macromolecules.  
This covalently linked structure is intercalated with numerous glycolipids such as lipoarabinomannan 
(LAM), the phosphatidyl inositol containing mannosides (PIMs), trehalose dimycolate (cord factor), trehalose-
monomycolate (TMM), which play an important role in virulence of Mtb. Lipids such as cord factor have been 
suggested to play an important role in the virulence of M. tuberculosis by inducing cytokine mediated events. 
LAM is also a major constituent of the mycobacteria cell wall and has been shown to induce TNF release from 
the macrophages which plays a significant role in bacterial killing [13]. 
The cell wall is the most common target of antituberculosis drugs, and many compounds that are in 
clinical use or under development target enzymes that synthesize distinct layers of the cell wall [68].  
The first committed step in the synthesis of decaprenyl phosphoryl-D-arabinose, the lipid donor of 
mycobacterial D-arabinofuranosyl residues during AG biosynthesis is the transfer of a 5-phosphoribosyl residue 
from phosphoribose diphosphate to decaprenyl phosphate to form decaprenylphosphoryl–5-phosphoribose.This 
step is catalyzed by a ribosyltransferase that has recently been characterized and shown to be essential for growth 
[69]. Other enzymes essential for arabinogalactan biosynthesis have been identified, including UDP-
galactopyranose mutase (glf gene), galactofuranosyl transferase and dTDP-6-deoxy-Llyxo- 4-hexulose reductase, 
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the enzyme that catalyzes the final step in the formation of dTDP-rhamnose. DTDP rhamnose is a product of 
four enzymes, RmlA–D, and a recent report has demonstrated that both RmlB and RmlC are essential for 
mycobacteria growth [70]. 
Because of the reasons cited above, genes involved in cell wall synthesis of mycobacteria have been 
exploited as targets for many anti-mycobacterial drugs. Several important TB drugs such as INH, ETA and EMB 
target mycobacterial cell wall synthesis. Current anti-TB drugs also include inhibitors of mycolic acid (isoniazid 
and ethambutol), arabinogalactan (ethambutol) and peptidoglycan (cycloserine).  Enzymes involved in this 
pathway have always been preferred targets in drug development efforts [71]. 
Recently, a number of new drug candidates that target M. tuberculosis cell wall have been identified 
and they are in Phase II clinical trials and in preclinical phase of development [72]. Thiolactomycin (TLM) 
targets two β-ketoacyl-acyl-carrier protein synthases, KasA and KasB enzymes that belong to the fatty acid 
synthase type II system involved in the fatty acid and mycolic acid biosynthesis [13]. TLM has also been shown 
to be active against MDR-TB clinical isolate. Cerulenin, an inhibitor of fatty acid synthesis, has also been shown 
to inhibit mycobacterial lipid synthesis and is active against M. tuberculosis in vitro with an MIC of 1.5-12.5 
mg/ml [61].  
Octane sulphonyl acetamide (OSA) has recently been identified as an inhibitor of fatty acid and mycolic 
acid biosynthesis in mycobacteria. The inhibitor was found to be active against both slow growers such as M. 
tuberculosis and also MDR-TB strains with a MIC of about 6.25-12.5mg/ml. These reports clearly suggest that 
several genes of the cell wall synthesis pathway and enzymes involved in fatty acid and mycolic acid synthesis 
could be good candidates for further drug development [73]. 
 
Genes of other metabolic pathways: 
Genes of some other metabolic pathways can also serve as possible targets for developing drugs against 
tuberculosis. Some of these genes include, mgtc, which codes for a putative Mg+2 transporter protein. This 
protein has been shown to be essential for the survival of mycobacteria both in macrophages and mice. The ∆-
mgtc mutant showed in vitro growth defects.  Similarly ∆-mbtB mutant deficient in synthesis of siderophores 
was unable to replicate within the macrophages. Failure of mycobacteria to survive in the absence of specific 
iron uptake system suggests the scarcity of this important nutrient in phagosomal environment [74]. 
The target Rv1712 is central to the phosphorylation of ATP to nucleoside diphosphate in the pyrimidine pathway 
[74]. The known TB drug target Rv0667 forms part of the purine and pyrimidine pathway and mutations in its 
gene rpoB lead to RIF’s resistance. With Rv1712 sharing this pathway it could be an attractive alternative target 
to inhibit this pathway [49]. 
 
ANTI-TUBERCULOSIS DRUGS IN CURRENT CLINICAL PRACTICE 
Chemotherapy regimens that are used for the treatment of all types of TB are classified as first- and second-line 
anti-TB drugs1.First-line anti-TB drugs include isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), 
ethambutol (EMB) and streptomycin (STM). INH and RMP are the two most commonly used drugs for 
treatment of TB. First-line anti-TB drugs are safe and effective if used correctly [6]. The effective treatment of 
MDR-TB is critical to reducing the spread of drug-resistant TB in the community. Currently, TB care and 
treatment has become more complicated due to the emergence of M/XDR-TB and Latent infection. Second-line 
drugs that are used for the treatment of MDR-TB are listed as aminoglycosides (kanamycin); e.g., amikacin (Am) 
and Kanamycin (Km); polypeptides: capreomycin (Cm), fluoroquinolones; e.g. ciprofloxacin; thioamides: e.g., 
ethionamide (Eto), cycloserine (Cs), and P-aminosalicylic acid (PAS). Second-line anti-TB drugs are less potent, 
need to be administered for a much longer time, are more toxic and are high-cost compared to first-line anti-TB 
drugs [7].   
KatG, PncA, EtaA/EthA are enzymes involved in the activation of the prodrugs isoniazid, pyrazinamide and 
ethionamide, respectively. 
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Table 1: Current tuberculosis drugs and their targets 
Drugs MIC 
(g/ml) 
Mechanism of action Targets Gene involved in 
resistance 
Isoniazid 0.01-0.20 Inhibition of cell wall (Mycoli 
acid synthesis) 
Enoyl acylcarrier protein,Reductase 
(InhA) 
KatG inhA 
Rifampin 0.05-0.50 Inhibition of RNA synthesis RNA polymerase beta subunit rpoB 
Pyrazinamide 20-100 Depletion of membrane energy Membrane energy metabolism pncA 
Ethambutol 1-5 Inhibion of cell 
wall(arabinogalactan synthesis) 
Arabinsyltransferase embCAB 
Streptomycin     2-8 Inhibition of protein synthesis Ribosomal S12 protein & 16s rRNA rpcl, rrs 
Kanamycin 1-8 inhibition of protein synthesis 16s rRNA                                              Rrs 
Capreomycin 4 Inhibition of protein synthesis 16s rRNA, 50s ribosome, rRNA 
methyltransferase (TlyA           
rrs, tlyA 
Fluoroquinolones 0.2–4.0 Inhibition of DNA synthesis DNA gyrase gyrA, gyrB 
Ethionamide 0.6–2.5 Inhibition of mycolic acid 
synthesis 
Acyl carrier protein reductase (InhA) inhA, etaA/ethA 
PAS 1–8 Inhibition of folate pathway 
andmycobactin synthesis? 
thymidylate synthase (ThyA)?  
 
thyAc 
Source: [75], [76] and Reviewed by [77] 
Status of current tuberculosis drug therapy: 
The current live vaccine Bacillus Calmette Guerin (BCG) attenuated strain of M bovis was introduced 
in 1922. It does not protect all age groups as its efficacy is globally variable, and it does not provide protection in 
most parts of the world where TB is effectively prevalent. It is not suitable to use for immune compromised 
patients. In addition to this, BCG only reduces dissemination of Mtb to the spleen and other organs, but it does 
not prevent mycobacterial growth in the lungs [7, 10]. 
Current TB therapy, also known as DOTS (directly observed treatment, short-course) consists of an 
initial phase of treatment with 4 drugs, INH, RIF, PZA and EMB, for 2 months daily, followed by treatment with 
INH and RIF for another 4 months, three times a week [3]. The targets of these drugs are varied. INH inhibits 
synthesis of mycolic acid, a cell well component (PZA targets cell membrane where as rifampin and 
streptomycin interferes with the initiation and streptomycin interferes with the initiation of RNA and protein 
synthesis respectively. EMB blocks biosynthesis of arabinogalactan, a major polysaccharide present in the 
mycobacterial cell wall and kanamycin and capreomycin, like streptomycin, inhibit protein synthesis through 
modification of ribosomal structures at the 16S rRNA [70]. Cycloserine prevents the synthesis of peptidoglycan, 
a constituent of cell wall [13] 
 
Limitation of current tuberculosis therapy: 
Recent reports indicate that, areas where there is a high incidence of MDR-TB, DOTS is failing to control the 
disease. In such circumstances, the second line drugs are prescribed in combination with DOTS. However, this 
combination of drugs is very expensive, has to be administered for a longer duration and has significant side 
effects. One major drawback of current TB therapy is that the drugs are administered for at least 6 months [71]. 
The length of therapy makes patient compliance difficult, and such patients become potent source of drug-
resistant strains. The second major and serious problem of current therapy is that most of the TB drugs available 
today are ineffective against persistent bacilli, except for RIF and PZA. RIF is active against both actively 
growing and slow metabolizing non-growing bacilli, whereas PZA is active against semi-dormant non-growing 
bacilli. However, there are still persistent bacterial populations that are not killed by any of the available TB 
drugs.  Therefore, there is a need to design new drugs that are more active against slowly growing or non-
growing persistent bacilli to treat the population at risk [14]. 
 
CONCLUSIONS AND RECOMMENDATIONS 
Tuberculosis is still a leading infectious disease worldwide. Along with the socio-economic and host factors that 
underlie this problem, a fundamental problem that hinders more effective TB control is the tenacious ability of 
Mycobacterium bacteria to persist in the host and to develop drug resistance, often as a consequence of poor 
compliance to lengthy therapy. Major obstacle in the cure and prevention of tuberculosis is posed by the latent or 
persistent mycobacterium infection. This is due to the fact that most of the currently available drugs are 
ineffective against latent infection. A better understanding on the physiology of mycobacteria during the latent 
period will help in the identification of new drug targets that can act on the persistent mycobacteria. The list of 
potential drug targets encoded in the genome of M. tuberculosis include genes involved in persistence or latency, 
cell wall synthesis, virulence, signal transduction, genes encoding transcription factors and enzymes of other 
metabolic pathways. Identification of these targets will to produce new drugs against tuberculosis that will 
overcome the limitations of existing drugs such as, prolonged chemotherapy, failure against persistent infection 
and multidrug resistance. 
Based on above conclusion the following recommendations are forwarded 
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 The lists of potential drug targets encoded in the genome of M. tuberculosis should be explored to 
identify new drug against tuberculosis that will overcome the limitation of existing drugs. 
 Research should involve testing new or reformulated drug, combination of different drugs to shorten 
therapy, supplementation and enhancements of existing drugs. 
 The existing (currently in use) drugs should be modified because of continuous development of drug 
resistance. 
 TB drugs should be tested and combined with different drugs to shorten therapy, to reduce toxicity and 
to enhance its activity. 
 More research should be conducted on molecular targets of Mycobacterium. 
 Researcher should actively participate in finding better and more effective drugs that reduce time of 
treatment and less toxic 
 
ABBREVIATIONS 
AG: Arabinogalactan; CB: Constraint Based; DOTS: Directly Observed Treatment, Short course Erp: 
Extracellular repeat protein; ICL: Isocitrate lysase; KEGG: Kyoto Encyclopedia of Gene and Genome; LAM: 
Lipoarabinomannan; Mbt: Mycobactin; MDR-TB: Multi Drug Resistant Tuberculosis; MIC: Minimum 
Inhibitory Concentration; NTM: Non Tuberculosis Mycobacteria; OMPs: Outer Membrane Proteins; PAS: Para-
aminosalicylic Acid; TCS: Tow Component System; TLM: Thiolactomycin; TNF: Tumor Necrosis Factor; 
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